Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
| completed |
| Phase 1 |
| 34 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Nov 21, 2017 |
| clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00562185 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01256268 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | completed | Phase 1 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02482090 | TIL Therapy for Metastatic Ovarian Cancer | completed | Phase 1 | 6 | Inge Marie SvaneOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00456495 | Effect of Ranibizumab on Malignant Conjunctival Neoplasia | completed | Phase 1 | 5 | The New York Eye Cancer CenterOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT02093871 | A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer(PISH-2) | suspended | Phase 1 | 20 | ThermalCore IncINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02237690 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | completed | Phase 1 | 30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | completed | Phase 1 | 22 | Verastem, Inc.INDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT00603460 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT00626873 | Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary | completed | Phase 1 | 67 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00976183 | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma | terminated | Phase 1 / Phase 2 | 18 | Gynecologic Oncology AssociatesOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01248949 | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | completed | Phase 1 | 162 | MedImmune LLCINDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01248273 | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer(PAZPET-1) | completed | Phase 1 | 16 | Imperial College LondonOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02262455 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 32 | Santa Maria BiotherapeuticsINDUSTRY | 1 | Feb 13, 2017 | clinicaltrials |
| NCT01308944 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01469793 | A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer | completed | Phase 1 | 71 | Genentech, Inc.INDUSTRY | 2 | Jan 10, 2017 | clinicaltrials |
| NCT00705640 | Vaccine Therapy in Treating Patients With Advanced Melanoma(Mel48) | completed | Phase 1 | 45 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT02970786 | Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | unknown | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT00842582 | Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer | withdrawn | Phase 1 | 0 | Loyola UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01335958 | Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | completed | Phase 1 | 77 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | terminated | Phase 1 | 6 | Tesaro, Inc.INDUSTRY | 0 | Oct 19, 2016 | clinicaltrials |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | unknown | Phase 1 / Phase 2 | 68 | JSehouliOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01384253 | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | completed | Phase 1 | 18 | Orano Med LLCINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | completed | Phase 1 | 6 | MorphotekINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 | 47 | AbbVieINDUSTRY | 3 | Sep 27, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2017source: clinicaltrials